Connor, Clark & Lunn Investment Management Ltd. Immunic, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Immunic, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 102,257 shares of IMUX stock, worth $110,437. This represents 0.0% of its overall portfolio holdings.
Number of Shares
102,257
Previous 59,874
70.79%
Holding current value
$110,437
Previous $66,000
154.55%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IMUX
# of Institutions
70Shares Held
56.2MCall Options Held
100Put Options Held
350K-
Bvf Inc San Francisco, CA8.9MShares$9.62 Million0.47% of portfolio
-
Avidity Partners Management LP Dallas, TX8.27MShares$8.93 Million0.84% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$7.88 Million1.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$6.04 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X05.1MShares$5.51 Million0.0% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $33M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...